Weight Loss$39.99–$75

Adipotide (FTTP): Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 3 sources cited

Overview

Adipotide (FTTP — Fat-Targeted Proapoptotic Peptide) is a peptidomimetic that selectively destroys the blood vessels feeding white adipose tissue, causing targeted fat cell death through vascular disruption. Originally developed at MD Anderson Cancer Center using cancer drug delivery technology repurposed for obesity, it produced dramatic fat loss in monkeys, between 7.4% and 14.7% of body weight over 28 days. However, it carries significant renal risks and is considered one of the more aggressive fat loss compounds in the research peptide space.

Mechanism of Action

Adipotide is a chimeric peptide with two functional domains working in concert. The targeting sequence (CKGGRAKDC) binds specifically to prohibitin, a protein overexpressed on the surface of endothelial cells lining blood vessels in white adipose tissue. This targeting peptide was identified through phage display screening and shows high selectivity for the adipose vasculature over blood vessels in other organs. Once the targeting domain binds prohibitin, the entire complex is internalized via receptor-mediated endocytosis. The second domain — the proapoptotic peptide D(KLAKLAK)2 — then triggers apoptosis by disrupting the mitochondrial membrane. This amphipathic peptide sequence inserts into the inner mitochondrial membrane, causing membrane depolarization, cytochrome c release, caspase cascade activation, and ultimately endothelial cell death. As the microvasculature supplying fat tissue is systematically destroyed, adipocytes are starved of oxygen and nutrients, undergoing apoptosis through ischemia. The dead fat cells are then cleared by macrophages. How durable the fat loss is has not been established. In the monkey study, weight, BMI and abdominal circumference kept falling for three weeks after dosing stopped, and in the original mouse work the fat loss was described as reversing obesity rather than as permanent. However, this same potency makes it a high-risk compound, as off-target effects on renal vasculature have been documented.

Adipotide (FTTP) Benefits: What the Research Shows

  • A 2011 study published in Science Translational Medicine reported that obese rhesus monkeys treated for 28 days lost between 7.4% and 14.7% of body weight, with BMI falling by 3.7% to 17.3%, while control monkeys did not.
  • MRI and DEXA imaging confirmed that the weight loss came mainly from fat, with abdominal white adipose tissue volume down 17.5% at the end of treatment and total body fat down further during recovery.
  • Abdominal circumference fell by 6.5% to 14.3% in nine of the ten treated monkeys, with one animal showing a 2% increase, indicating preferential abdominal fat loss.
  • Dose-dependent kidney findings were documented in treated monkeys: raised serum creatinine, glucosuria and proteinuria, with lesions scored minimal to moderate and most changes resolving within 28 days of stopping, though one monkey in each study still had slightly raised creatinine at the end of recovery.
  • The phage display technology used to discover adipotide's targeting sequence has since been validated in cancer drug delivery applications, confirming the tissue-targeting approach.
  • Metabolic parameters including insulin sensitivity improved in parallel with fat loss in treated primates.

Adipotide (FTTP) Dosage

  • Primate study protocol: 0.43 mg/kg subcutaneous injection daily for 28 days, which produced 7.4% to 14.7% body weight loss in obese rhesus monkeys.
  • No established human dosing protocol exists — this compound is strictly research-use only and has not entered human clinical trials.
  • Anecdotal research community protocols suggest starting at significantly lower doses (0.1–0.2 mg/kg) to assess individual tolerance before any escalation.
  • Kidney function monitoring (serum creatinine, BUN, urinalysis) is absolutely essential before, during, and after any research use, given documented renal effects.
  • Hydration should be maintained at high levels during use to support renal function and facilitate clearance of cellular debris from fat cell apoptosis.
  • Should not be used without direct medical supervision due to the inherent risks of vascular disruption in a non-targeted-therapy setting.
  • Typical research cycle: no longer than 28 days, with pre- and post-cycle blood work including comprehensive metabolic panel and urinalysis.
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

Adipotide (FTTP) Side Effects & Safety

Known Side Effects

  • Renal tubular damage — the most significant and well-documented side effect. Prohibitin is expressed in renal vasculature, making the kidneys a partial off-target site. Manifests as elevated creatinine, proteinuria, and potential acute kidney injury.
  • Dehydration — the rapid destruction of adipose tissue and associated inflammatory response increases fluid requirements significantly.
  • Injection site reactions — pain, redness, and swelling at injection sites are commonly reported.
  • Fatigue and malaise — the systemic inflammatory response to widespread fat cell death can produce flu-like symptoms.
  • Reduced food intake — treated monkeys ate less while losing weight, and the authors could not rule out mild nausea as a contributor, so part of the weight loss may come from eating less rather than from fat cell death alone.
  • Potential for irreversible fat loss in treated areas — while this is the intended effect, it means dosing errors or asymmetric application could theoretically produce cosmetically uneven results.

Safety Profile

Adipotide carries one of the highest risk profiles of any research peptide. The primary concern is renal toxicity — prohibitin is not exclusively expressed on adipose vasculature, and the kidneys appear to be a significant off-target tissue. In primate studies, reversible proximal tubular damage was documented, but the long-term renal consequences of repeated exposure are unknown. Individuals with any pre-existing kidney disease, diabetes (with potential subclinical nephropathy), or those taking nephrotoxic medications should absolutely avoid this compound. There is no human clinical trial data, no established safety margins, and no antidote if adverse effects occur. The mechanism is inherently aggressive — it kills cells — and unlike most peptides, its effects may be partially irreversible. It is contraindicated in anyone with renal impairment, cardiovascular disease, clotting disorders, or who is pregnant/breastfeeding. This compound should only be considered in a supervised research context with comprehensive blood work monitoring.

What to Expect

Days 1–5: Injection site reactions are common. Systemic effects are minimal as the vascular disruption process begins at the molecular level. Increased thirst and mild fatigue may occur. Days 6–14: Fat loss becomes noticeable and surprisingly rapid. Users in research contexts report visible reduction in abdominal fat. Fatigue and flu-like symptoms may peak as the inflammatory response to fat cell death is greatest. Urine output should be monitored. Days 15–28: Continued fat loss. In the monkey study the fat loss carried on through the four-week recovery period after dosing stopped. Renal markers should be monitored at least weekly. Body composition changes are dramatic compared to any other peptide. Post-cycle: Fat loss effects may persist as destroyed vasculature and adipocytes are slowly cleared. Full renal recovery should be confirmed through blood work. Whether any of the fat loss is permanent is unknown; in the monkey study weight and fat kept falling for three weeks after the last dose, and the animals were not followed beyond the recovery period.

Common Stacks

Storage & Handling

Store lyophilized powder at -4°F to 36°F (-20°C to 2°C). Protect from light and moisture. After reconstitution with bacteriostatic water, refrigerate at 36–46°F (2–8°C) and use within 21 days. Do not freeze reconstituted solution. Shelf life of unreconstituted powder is approximately 12–18 months when stored properly.

Pricing & Available Variants

$39.99 – $75price range
5mg10mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Barnhart KF, Christianson DR, Hanley PW, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011.
  2. Kolonin MG, Saha PK, Chan L, et al. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004.
  3. Registered studies of adipotide. ClinicalTrials.gov. 2026.

Related Peptides

Track Adipotide (FTTP) in Your Protocol

Log your Adipotide (FTTP) doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free